Table 2.
Overall survival | HR (95 % CI) | P value |
Crude | 3.01 (1.70–5.33) | <0.001 |
Adjusted for age | 2.99 (1.68–5.33) | <0.001 |
Adjusted for age group (≥50 vs. <50) | 3.07 (1.72–5.48) | <0.001 |
Adjusted for grade | 3.08 (1.71–5.57) | <0.001 |
Adjusted for stage | 3.09 (1.73–5.53) | <0.001 |
Adjusted for age, tumor grade and tumor stage | 3.19 (1.74–5.86) | <0.001 |
Adjusted for age, tumor grade, tumor stage, and race | 3.24 (1.75–5.99) | <0.001 |
Adjusted for age group (≥50 vs. <50), tumor grade, tumor stage, and race | 3.40 (1.83–6.33) | <0.001 |
Adjusted for BMI | 3.24 (1.78–5.89) | <0.001 |
Adjusted for tumor grade, tumor stage, race, and BMI | 3.50 (1.87–6.54) | <0.001 |
Time to tumor recurrencea | ||
Crude | 2.08 (1.04–4.16) | 0.039 |
Adjusted for age | 2.59 (1.27–5.26) | 0.009 |
Adjusted for age group (≥50 vs. <50) | 2.65 (1.29–5.44) | 0.008 |
Adjusted for grade | 2.06 (1.01–4.18) | 0.046 |
Adjusted for stage | 2.01 (1.00–4.04) | 0.051 |
Adjusted for grade and stage | 2.00 (0.97–4.09) | 0.059 |
Adjusted for race | 2.17 (1.08–4.38) | 0.030 |
Adjusted for BMI | 2.37 (1.16–4.83) | 0.017 |
Adjusted for BMI and grade | 2.32 (1.13–4.73) | 0.021 |
Adjusted for BMI and stage | 2.32 (1.13–4.76) | 0.022 |
aFive out of 148 (3.4 %) subjects who never became disease free were removed from TTR analyses